Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumours

ABSTRACT Testicular germ cell tumours (TGCTs) respond well to cisplatin-based therapy. However, cisplatin resistance and poor outcomes do occur. It has been suggested that a shift towards DNA hypermethylation mediates cisplatin resistance in TGCT cells, although there is little direct evidence to support this claim. Here we utilized a series of isogenic cisplatin-resistant cell models and observed a strong association between cisplatin resistance in TGCT cells and a net increase in global CpG and non-CpG DNA methylation spanning regulatory, intergenic, genic and repeat elements. Hypermethylated loci were significantly enriched for repressive DNA segments, CTCF and RAD21 sites and lamina associated domains, suggesting that global nuclear reorganization of chromatin structure occurred in resistant cells. Hypomethylated CpG loci were significantly enriched for EZH2 and SUZ12 binding and H3K27me3 sites. Integrative transcriptome and methylome analyses showed a strong negative correlation between gene promoter and CpG island methylation and gene expression in resistant cells and a weaker positive correlation between gene body methylation and gene expression. A bidirectional shift between gene promoter and gene body DNA methylation occurred within multiple genes that was associated with upregulation of polycomb targets and downregulation of tumour suppressor genes. These data support the hypothesis that global remodelling of DNA methylation is a key factor in mediating cisplatin hypersensitivity and chemoresistance of TGCTs and furthers the rationale for hypomethylation therapy for refractory TGCT patients.

[1]  Nenggang Zhang,et al.  Cohesin Subunit RAD21: from Biology to Disease. , 2020, Gene.

[2]  S. de Jong,et al.  Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. , 2020, Cancer treatment reviews.

[3]  R. Henrique,et al.  Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives , 2020, Cancers.

[4]  R. Huddart,et al.  Genomic landscape of platinum resistant and sensitive testicular cancers , 2020, Nature Communications.

[5]  S. Shariat,et al.  Epigenetic alterations of testicular germ cell tumours. , 2020, Current opinion in urology.

[6]  Ashwini Patil,et al.  Aberrant epigenetic inactivation of RASSF1A and MGMT gene and genetic mutations of KRAS, cKIT and BRAF in Indian testicular germ cell tumours. , 2020, Cancer genetics.

[7]  S. Fosså,et al.  Testicular Cancer Survivorship. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  M. Spinella,et al.  Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors , 2019, Cancer drug resistance.

[9]  J. Lavoie,et al.  Current Management of Disseminated Germ Cell Tumors. , 2019, The Urologic clinics of North America.

[10]  M. Spinella,et al.  Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors , 2019, Cancers.

[11]  Jop Kind,et al.  Lamina Associated Domains and Gene Regulation in Development and Cancer , 2019, Cells.

[12]  H. Schorle,et al.  Epigenetic drugs and their molecular targets in testicular germ cell tumours , 2019, Nature Reviews Urology.

[13]  Zhaojian Gong,et al.  A network-based approach to identify DNA methylation and its involved molecular pathways in testicular germ cell tumors , 2019, Journal of Cancer.

[14]  Yi-Xun Liu,et al.  Testicular germ cell tumor: a comprehensive review , 2019, Cellular and Molecular Life Sciences.

[15]  P. Qiu,et al.  Correlation Patterns Between DNA Methylation and Gene Expression in The Cancer Genome Atlas , 2019, Cancer informatics.

[16]  L. Looijenga,et al.  Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic , 2019, International journal of molecular sciences.

[17]  C. Bokemeyer,et al.  5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells , 2018, International journal of molecular sciences.

[18]  K. Kalavska,et al.  Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors , 2018, Current Oncology Reports.

[19]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[20]  D. D. De Carvalho,et al.  Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer. , 2018, Trends in cancer.

[21]  Joshua M. Stuart,et al.  Integrated Molecular Characterization of Testicular Germ Cell Tumors , 2018, Cell reports.

[22]  R. Henrique,et al.  Targeting DNA Methyltranferases in Urological Tumors , 2018, Front. Pharmacol..

[23]  K. Nakai,et al.  Differential landscape of non-CpG methylation in embryonic stem cells and neurons caused by DNMT3s , 2017, Scientific Reports.

[24]  L. Hou,et al.  Prediction of genome-wide DNA methylation in repetitive elements , 2017, Nucleic acids research.

[25]  K. Sadler,et al.  DNA Methylation, Nuclear Organization, and Cancer , 2017, Front. Genet..

[26]  L. Einhorn,et al.  Testicular cancer update. , 2017, Clinical advances in hematology & oncology : H&O.

[27]  A. Kirschner,et al.  Current Management of Refractory Germ Cell Tumors and Future Directions , 2017, Current Oncology Reports.

[28]  B. Christensen,et al.  Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine , 2016, Oncotarget.

[29]  Jean-Philippe Fortin,et al.  Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi , 2016, bioRxiv.

[30]  Peter W. Laird,et al.  Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes , 2016, Nucleic acids research.

[31]  D. O. Vidal,et al.  MGMT and CALCA promoter methylation are associated with poor prognosis in testicular germ cell tumor patients , 2016, Oncotarget.

[32]  P. Meltzer,et al.  Imprints and DPPA3 are bypassed during pluripotency- and differentiation-coupled methylation reprogramming in testicular germ cell tumors , 2016, Genome research.

[33]  Peter A. Jones,et al.  Targeting the cancer epigenome for therapy , 2016, Nature Reviews Genetics.

[34]  Hongbo Liu,et al.  Systematic identification and annotation of human methylation marks based on bisulfite sequencing methylomes reveals distinct roles of cell type-specific hypomethylation in the regulation of cell identity genes , 2015, Nucleic acids research.

[35]  Nathan C. Sheffield,et al.  LOLA: enrichment analysis for genomic region sets and regulatory elements in R and Bioconductor , 2015, Bioinform..

[36]  B. Carver,et al.  Late Relapse of Testicular Germ Cell Tumors. , 2015, The Urologic clinics of North America.

[37]  L. Looijenga,et al.  An oncofetal and developmental perspective on testicular germ cell cancer. , 2014, Seminars in cancer biology.

[38]  S. Pinney.  Mammalian Non-CpG Methylation: Stem Cells and Beyond , 2014, Biology.

[39]  L. Looijenga,et al.  Seminoma and Embryonal Carcinoma Footprints Identified by Analysis of Integrated Genome-Wide Epigenetic and Expression Profiles of Germ Cell Cancer Cell Lines , 2014, PloS one.

[40]  P. Andrews,et al.  Aza-deoxycytidine induces apoptosis or differentiation via DNMT3B and targets embryonal carcinoma cells but not their differentiated derivatives , 2014, British Journal of Cancer.

[41]  K. Hansen,et al.  Functional normalization of 450k methylation array data improves replication in large cancer studies , 2014, Genome Biology.

[42]  R. Weksberg,et al.  Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray , 2013, Epigenetics.

[43]  B. Christensen,et al.  Acute Hypersensitivity of Pluripotent Testicular Cancer-Derived Embryonal Carcinoma to Low-Dose 5-Aza Deoxycytidine Is Associated with Global DNA Damage-Associated p53 Activation, Anti-Pluripotency and DNA Demethylation , 2012, PloS one.

[44]  R. Motzer,et al.  Progression‐free and overall survival in patients with relapsed/refractory germ cell tumors treated with single‐agent chemotherapy: Endpoints for clinical trial design , 2012, Cancer.

[45]  J. Richter,et al.  Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance , 2010, The Journal of pathology.

[46]  E. Dmitrovsky,et al.  High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. , 2009, Cancer research.

[47]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Bacik,et al.  Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors , 2004, Molecular Cancer.